PDF(Pubmed)
Abstract：
Over the past few years, dual-targeted chimeric antigen receptor (CAR) T-cell therapy has been employed in the management of hematological malignancies to mitigate treatment failure, particularly in cases of antigen escape. The most widely used approaches include CD19/CD20, CD20/CD22, and BCMA/CD19 CAR T-cells. Alternative immune cells, including natural killer T cells and invariant natural killer T cells, exhibit innate anti-tumor activity and reduced toxicity. This review summarizes several recent clinical trial reports and preclinical studies from the 2023 American Society of Hematology (ASH) annual meeting on dual-targeted CAR T-cell immunotherapy for hematological malignancies.
摘要：
在过去的几年里，双靶向嵌合抗原受体（CAR）T细胞疗法已用于血液系统恶性肿瘤的治疗，以减轻治疗失败，特别是在抗原逃逸的情况下。最广泛使用的方法包括CD19/CD20、CD20/CD22和BCMA/CD19CART细胞。替代免疫细胞，包括自然杀伤T细胞和不变的自然杀伤T细胞，表现出先天的抗肿瘤活性和降低的毒性。这篇综述总结了2023年美国血液学会（ASH）关于血液恶性肿瘤双靶向CART细胞免疫治疗的年度会议的一些最新临床试验报告和临床前研究。
